Atossa Therapeutics Celebrates Weill Cornell Medicine’s $2.3 Million Grant for Young Breast Cancer Patients
Seattle, WA, Feb. 5, 2025 – Atossa Therapeutics, Inc. (Nasdaq: ATOS), a leading clinical-stage biopharmaceutical company specializing in the prevention and treatment of breast cancer, extends its warm congratulations to Dr. Tessa Cigler, esteemed member of Atossa’s Board of Directors, and the dedicated team at Weill Cornell Medicine in New York City. The team has recently been awarded a five-year, $2.3 million grant from the Centers for Disease Control and Prevention (CDC) to fund initiatives aimed at enhancing equitable access to care, improving quality of life, and boosting survival outcomes for young breast cancer patients in New York City.
About the Grant
The CDC grant, part of the National Breast and Cervical Cancer Early Detection Program, will support the Weill Cornell Medicine team’s efforts to address disparities in breast cancer care and outcomes among young women in New York City. The program aims to improve access to early detection, diagnosis, and treatment services, as well as provide comprehensive support for patients and their families.
Impact on Young Breast Cancer Patients
The grant will enable the Weill Cornell Medicine team to expand their reach and provide vital resources to young breast cancer patients who might otherwise face barriers to care. This includes initiatives such as:
- Outreach and education: Increasing awareness and knowledge about breast cancer symptoms, risks, and preventative measures in underserved communities.
- Access to screenings: Offering free or low-cost mammography and other diagnostic services to eligible patients.
- Navigational support: Assisting patients in navigating the complex healthcare system, from diagnosis to treatment and beyond.
- Patient-centered care: Providing personalized care plans and support services tailored to each patient’s unique needs.
Global Implications
The success of this initiative in New York City could pave the way for similar programs in other cities and communities across the United States and around the world. By addressing disparities in breast cancer care and outcomes, we can ensure that all individuals – regardless of their age, race, ethnicity, or socioeconomic status – have access to the resources and support they need to fight this disease effectively.
Atossa Therapeutics’ Role
Atossa Therapeutics is proud to support Dr. Cigler and the Weill Cornell Medicine team in their mission to improve breast cancer care for young patients. As a company dedicated to the prevention and treatment of breast cancer, Atossa is committed to working with leading healthcare organizations and researchers to advance the field and make a difference in the lives of patients.
Conclusion
The $2.3 million grant awarded to Weill Cornell Medicine by the CDC is a significant step forward in the fight against breast cancer, particularly for young patients in New York City. This initiative will help bridge the gap in care and resources, ensuring that all individuals have the opportunity to receive the best possible treatment and support. Atossa Therapeutics is proud to support this important work and looks forward to the positive impact it will have on the lives of countless young breast cancer patients.
Together, we can make a difference in the world of breast cancer care and help create a future where every patient has access to the resources and support they need to thrive.
